285 related articles for article (PubMed ID: 27743353)
1. Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.
Fruehauf S; Otremba B; Stötzer O; Rudolph C
Adv Ther; 2016 Nov; 33(11):1983-2000. PubMed ID: 27743353
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
Aapro M; Bokemeyer C; Ludwig H; Gascón P; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; MacDonald K; Abraham I
J Geriatr Oncol; 2017 Mar; 8(2):86-95. PubMed ID: 27829539
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
5. Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.
Kamioner D; Fruehauf S; Maloisel F; Cals L; Lepretre S; Berthou C
BMC Cancer; 2013 Nov; 13():547. PubMed ID: 24237790
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
[TBL] [Abstract][Full Text] [Related]
7. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
[TBL] [Abstract][Full Text] [Related]
8. MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
Gascón P; Krendyukov A; Höbel N; Aapro M
Eur J Haematol; 2018 Mar; 100(3):241-246. PubMed ID: 29171913
[TBL] [Abstract][Full Text] [Related]
9. G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study.
Phelip JM; Souquet PJ; Hacini M; Chehimi M; Bourgeois V; Bennoune R; Tredan O
Cancer Treat Res Commun; 2023; 35():100690. PubMed ID: 36780734
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
[TBL] [Abstract][Full Text] [Related]
12. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
[TBL] [Abstract][Full Text] [Related]
14. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).
Aapro M; Ludwig H; Bokemeyer C; Gascón P; Boccadoro M; Denhaerynck K; Krendyukov A; Gorray M; MacDonald K; Abraham I
Ann Oncol; 2016 Nov; 27(11):2039-2045. PubMed ID: 27793849
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
[TBL] [Abstract][Full Text] [Related]
20. Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Pettengell R; Bias P; Mueller U; Lang N
Support Care Cancer; 2016 Jun; 24(6):2677-84. PubMed ID: 26780505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
